The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company’s Precision Olfactory Delivery™ or POD™ technology. Patent number 9,919,117, entitled “NOZZLES FOR NASAL DRUG DELIVERY,” is directed to nozzles used in the POD™ technology to allow drug administration into the deep...

New Vice President will build clinical operations department while leading several early stage clinical programs On December 6th, Impel NeuroPharma, Inc. announced the appointment of seasoned clinical operations leader, Meghan Swardstrom, as Vice President of Clinical Operations. “Impel has made tremendous progress in just twelve months with one clinical program already completing...

At the beginning of September, Impel NeuroPharma moved its headquarters to 201 Elliot, a new biotech lab and office building. “The office gives us capacity to grow, it takes us from startup mode to small company mode.” Dr. John Hoekman, Impel's CEO is quoted as saying in an article from the...

The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company's POD™ device. Patent number 9,550,036, entitled "NASAL DRUG DELIVERY DEVICE," is directed to a device for delivery of compounds to the nasal cavity and methods of using the same.   Impel is...